Third Harmonic Bio IncNASDAQ:THRD
- LAST PRICE11.5650
- TODAY'S CHANGE (%)0.1350 (1.1811%)
- Bid / Lots11.5100/ 2
- Ask / Lots11.6400/ 4
- Open / Previous Close11.4000 / 11.4300
- Day Range
- 52 Week Range
- Volume38,333
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | THRD |
|---|---|---|
| 09:32 ET | 3713 | 11.73 |
| 09:34 ET | 6316 | 11.79 |
| 09:36 ET | 8816 | 11.91 |
| 09:38 ET | 2400 | 12.15 |
| 09:39 ET | 624 | 11.925 |
| 09:41 ET | 519 | 11.99 |
| 09:43 ET | 200 | 11.935 |
| 09:45 ET | 1978 | 11.9 |
| 09:48 ET | 200 | 11.87 |
| 09:50 ET | 669 | 11.845 |
| 09:52 ET | 254 | 11.84 |
| 09:54 ET | 626 | 11.83 |
| 09:56 ET | 459 | 11.785 |
| 09:57 ET | 565 | 11.6 |
| 09:59 ET | 473 | 11.63 |
| 10:01 ET | 1521 | 11.43 |
| 10:03 ET | 200 | 11.43 |
| 10:06 ET | 200 | 11.47 |
| 10:08 ET | 200 | 11.53 |
| 10:10 ET | 354 | 11.52 |
| 10:12 ET | 1200 | 11.5699 |
| 10:14 ET | 200 | 11.47 |
| 10:15 ET | 100 | 11.47 |
| 10:17 ET | 100 | 11.51 |
| 10:21 ET | 100 | 11.42 |
| 10:24 ET | 200 | 11.41 |
| 10:26 ET | 200 | 11.52 |
| 10:28 ET | 1166 | 11.52 |
| 10:30 ET | 100 | 11.54 |
| 10:32 ET | 285 | 11.565 |
Mar 28, 2024
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors, from 8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
8:30AM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors, from 8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 26, 2024
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results, from 8:05AM ET on Tuesday Mar 26, 2024 by Dow Jones
8:05AM ET on Tuesday Mar 26, 2024 by Dow JonesPress Release: Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results, from 8:05AM ET on Tuesday Mar 26, 2024 by Dow Jones
8:05AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Third Harmonic Bio Inc | 465.4M | -12.2x | --- |
Mereo BioPharma Group PLC | 371.7M | -10.2x | --- |
Skye Bioscience Inc | 476.2M | -2.7x | --- |
ACELYRIN Inc | 480.0M | -0.5x | --- |
LENZ Therapeutics Inc | 446.6M | -1.1x | --- |
Kalvista Pharmaceuticals Inc | 485.2M | -3.7x | --- |
Company Information
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is engaged in the development of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. It is focused on developing oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company’s clinical studies demonstrate that KIT inhibition is used for the treatment of a range of mast-cell-mediated inflammatory diseases, and that a titratable, oral, intracellular small molecule inhibitor may provide the optimal therapeutic profile against this target.
Contact Information
- Headquarters
- 1700 Montgomery Street, Suite 210SAN FRANCISCO, CA, United States 94111
- Phone
- 209-727-2457
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- Chief Executive Officer, Director
- Natalie Holles
- Chief Financial and Business Officer and Principal financial officer
- Christopher Murphy
- Chief Administrative Officer
- Julie Person
- Chief Medical Officer
- Edward Conner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $465.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.95 |
Book Value | $6.71 |
P/E Ratio | -12.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
